Name: Tedizolid Phosphate
Price: 267.00 USD

- Overview
  - Tedizolid Phosphate is a second-generation oxazolidone antibiotic. It is a phosphate ester precursor to Tedizolid, the active compound. It is bacteriostatic against Gram-positive organisms.
    Tedizolid Phosphate was developed by Cubist Pharmaceuticals, following acquistion of Trius Pherapeutics. It differs from other oxazolidinones by having a modified side chain at the C-5 position of the oxazolidinone nucleus which confers activity against certain linezolid-resistant pathogens. It also has an optimized C- and D-ring system that improves its potency via addiitonal binding site interactions. The compound was formerly known as Torezolid. Tedizolid is bacteriostatic against Gram-positive organisms. As with linezolid, Tedizolid is a weak, reversible MAO inhibitor.
    Tedizolid Phosphate is slighty soluble in DMSO, but insoluble in water and ethanol.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Tedizolid binds to the 23S rRNA of the 50S ribosomal subunit, preventing the formation of the 70S initiation complex and inhibiting protein synthesis.
- Properties
  - CAS Number
    
    856867-55-5
    
    Molecular Formula
    
    C17H16FN6O6P
    
    Molecular Weight
    
    450.32
    
    Appearance
    
    White to off-white powder
    
    Solubility
    
    Soluble in DMSO (36 mg/mL), sparingly soluble in water (0.1 mg/mL)
    
    Other Properties
    
    Source: Synthetic
    Purity Level: ≥99.0% (by HPLC)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Tedizolid is effective against Gram-positive bacteria including MRSA and VRE, and linezolid-resistant strains.
    
    Microbiology Applications: Tedizolid inhibited all 28 isolates of penicillin-resistant Streptococcus pneumoniae (PRSP) using an in vitro mouse model with 0.25 µg/mL, which was 4-fold more potent than Linezolid (Choi et al, 2012).
    In a murine model of hematogenous pulmonary ijfection, Tedizolid showed antimicrobial and immunomodulatory results superior to vancomycin (ref)
    Oxazolidinone antibacterials as a class are generally capable of overcoming resistance to other bacterial protein synthesis inhibitors.